On October 26, 2021 Indivumed, the developer of the world’s leading discovery platform for precision oncology, and Biognosys, a leader in next-generation proteomics solutions for discovery and drug development, reported the extension of their strategic partnership to provide biopharmaceutical customers with immunopeptidomic perspectives in drug discovery in oncology (Press release, Indivumed, OCT 26, 2021, View Source [SID1234591979]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The partnership builds on each company’s unique capabilities in omics research, with Biognosys providing proteomic technology and solutions based on mass spectrometry, and Indivumed providing high-quality samples and data, as well as its multi-discovery AI system. -omics, nRavel .
The initial partnership created in December 2019 aimed to enrich IndivuType, Indivumed’s multi-omic cancer database, with proteomic data from thousands of samples analyzed by Biognosys. Since then, Indivumed and Biognosys have successfully collaborated on various clinical research projects and published the results of a large-scale lung cancer study at AACR (Free AACR Whitepaper) 2020 , unveiling new biomarkers for tumor biology. Building on this success, the companies are extending their partnership with immunopeptidomics research.
Immunopeptides play an essential role in the immune system, and can be analyzed to support the development of personalized treatments, in particular for cancers, vaccines, and infectious and autoimmune diseases. Mass spectrometry is currently the only technology to reliably measure and identify immunopeptide profiles from large-scale biological samples.
Biognosys Immunopeptide Stream deploys its patented Hyper Reaction Monitoring (HRM ) mass spectrometry technology for proteome quantification, in conjunction with its proprietary data analysis software Spectronaut and SpectroMine to identify over 10,000 unique immunopeptides from small quantity samples. Highly efficient and scalable, the flux can be used in large-scale clinical studies.
Indivumed can then provide biopharmaceutical customers with further validation and insight on the immunopeptide signatures identified through the Biognosys feed, leveraging IndivuType, the multi-omics cancer database , and the nRavel analytical platform. in order to optimize R&D activities and new discovery programs for individualized therapy.
Biognosys present validate the sensitivity and reproducibility of the workflow during the annual conference of the American Society of Mass Spectrometry (ASMS) on 1 st November Philadelphia. Indivumed will present a clinically relevant multi-omic analysis at the BioData World Congress on November 2 in Basel.
The new immunopeptidomics offer is already being applied successfully to third-party biopharmaceutical companies in order to optimize their drug discovery efforts.
Lukas Reiter, PhD, Chief Technology Officer, Biognosys: " Biognosys HRM technology uniquely addresses key challenges in immunopeptidomics research. Using only small amounts of tissue, our optimized flow provides a comprehensive biological perspective on the immune system. We are delighted to apply this solution to Indivumed’s valuable tissue samples and to support drug discovery in areas of significant unmet need. "
Roald Forsberg, Sales Manager and Head of IndivuType Business Unit at Indivumed: "With our IndivuType database and our nRavel AI system , we have the perfect opportunity to make new discoveries about the role of the immune response in the tumor microenvironment, and to develop novel immunotherapies against cancer.This extended partnership with Biognosys gives us the opportunity to validate and deepen our findings using mass spectrometry technology that will accelerate the transition between these discoveries and the practice of personalized oncology. "